Helping Patients Afford SYLVANT®
Support for Patients Using Commercial or Private Insurance
Janssen CarePath Savings Program for SYLVANT®
The Janssen CarePath Savings Program may provide a rebate for patients' out-of-pocket SYLVANT® costs. Patients may be eligible if they have been prescribed SYLVANT® and currently have commercial insurance that covers medication costs for SYLVANT®. If eligible, your patients may receive a rebate for their out-of-pocket SYLVANT® medication expenses after they pay their full co-pay amount to their healthcare provider when they receive their treatment. Patients will receive a rebate up to $1,000 per infusion for their medication costs and pay $50 per infusion. Costs of IV infusion services are not covered by this program. The program exhausts 12 months from the patient's first eligible date of service. Patients may re-enroll annually to continue receiving a benefit from the program. This program is not available to individuals who use any state of federal government subsidized healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense of Veterans Administration. Click here for additional program details, including eligibility and restrictions, or to download the enrollment form.
Support for patients using government insurance or patients without insurance coverage
JanssenPrescriptionAssistance.com provides information on affordability programs and up-to-date information about independent foundations that may have available funding to help minimize drug costs for SYLVANT®.
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) provides free prescription medications to eligible individuals who do not have insurance coverage for their medications and do not have adequate financial resources to pay for them. Please have your patient contact a JJPAF program specialist at 800-652-6227, 9 AM to 6 PM ET, or visit the foundation Web site at JJPAF.org to see if they might qualify for assistance.
SYLVANT® (siltuximab) is indicated for the treatment of patients with Multicentric Castleman's Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Limitation of Use. SYLVANT® was not studied in patients with MCD who are HIV-positive or HHV-8 positive because SYLVANT® did not bind to virally produced IL-6 in a nonclinical study.
CONTRAINDICATIONS – Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT®.
Concurrent Active Severe Infections – Do not administer to patients with severe infections until the infection resolves. SYLVANT® may mask signs and symptoms of acute inflammation including suppression of fever and of acute phase reactants such as C-reactive protein (CRP). Monitor patients closely for infections. Institute prompt anti-infective therapy and do not administer further SYLVANT® until the infection resolves.
Vaccinations – Do not administer live vaccines to patients receiving SYLVANT® because interleukin-6 (IL-6) inhibition may interfere with the normal immune response to new antigens.
Infusion Related Reactions and Hypersensitivity – Stop the infusion if the patient develops signs of anaphylaxis. Discontinue further therapy.
Stop the infusion if the patient develops mild to moderate infusion reactions. If the reaction resolves, the infusion may be restarted at a lower infusion rate. Consider medicating with antihistamines, acetaminophen, and corticosteroids. Discontinue SYLVANT® if the patient does not tolerate the infusion following these interventions.
Administer SYLVANT® in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.
Gastrointestinal (GI) Perforation – Use with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with symptoms that may be associated with or suggestive of GI perforation.
Adverse Reactions – The most common adverse reactions (>10% compared to placebo) in the MCD clinical trial were pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.
Drug Interactions – Cytochrome P450 (CYP450) Substrates – Upon initiation or discontinuation of SYLVANT®, in patients being treated with CYP450 substrates with narrow therapeutic index, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) as needed and adjust dose. Exercise caution when SYLVANT® is co-administered with CYP3A4 substrate drugs where a decrease in effectiveness would be undesirable (e.g., oral contraceptives, lovastatin, atorvastatin).
Please click here to read full Prescribing Information for SYLVANT®.